Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use

Heinzerling, Keith G.; Swanson, Aimee‐Noelle; Hall, Timothy M.; Yi, Yi; Wu, Yingnian; Shoptaw, Steven J.

doi:10.1111/add.12636

Cited by 64Substance Abuse Treatment and OutcomesOpioid Use Disorder TreatmentNeurotransmitter Receptor Influence on Behavior

Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use

Open access

Heinzerling, Keith G., Swanson, Aimee‐Noelle, Hall, Timothy M., Yi, Yi, Wu, Yingnian, Shoptaw, Steven J.·2014·Addiction

DOI 10.1111/add.12636PMC PMC4192025

Open this paper in CoChat — free account Open PDF

Abstract

AIMS: Two previous randomized trials found an effect for bupropion in reducing methamphetamine use in the subgroup with lower frequency of methamphetamine use at baseline. This study aimed to replicate these results by comparing bupropion versus placebo in methamphetamine-dependent participants with less than daily methamphetamine use at baseline. METHODS: Methamphetamine-dependent volunteers reporting methamphetamine use on ≤29 of past 30 days were randomized to bupropion 150 mg twice daily (n = 41) or placebo (n = 43) and out-patient counseling for 12 weeks. The primary outcome was the proportion achieving end-of-treatment (EOT) methamphetamine abstinence (weeks 11 and 12) for bupropion versus placebo. A post-hoc analysis compared EOT abstinence by medication adherence assessed via plasma bupropion/hydroxybupropion level. RESULTS: There was no significant difference in EOT abstinence between bupropion (29%, 12 of 41) and placebo (14%, six of 43; P = 0.087). Among participants receiving bupropion, EOT abstinence was significantly higher in participants assessed as medication adherent by plasma bupropion/hydroxybupropion levels (54%, seven of 13) compared to non-adherent participants (18%, five of 28; P = 0.018). Medication adherence by plasma levels was low (32%). CONCLUSIONS: Bupropion may be efficacious for reducing methamphetamine in people with less than daily baseline methamphetamine use, but the evidence remains inconclusive.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/add.12636

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Various pharmacologic and psychosocial therapies for MUD/PMU have been explored in the literature.
“Although various pharmacologic (e.g., bupropion [22, 23], mirtazapine [24, 25], varenicline [26]) and psychosocial (e.g., cognitive behavioural therapy [27], contingency management [28, 29], Matrix model [30]) therapies for MUD/PMU have been explored in the literature, the best approach to treatment remains unclear.”
From Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature (2023) · cites this paper as [23]
Among studies reporting race (n = 34), the majority of patients were Caucasian in all but four studies.
“Among studies reporting race (n = 34), the majority of patients were Caucasian in all but four studies [23, 69, 73, 102].”
From Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature (2023) · cites this paper as [23]
The Results section (Sample Characteristics; page unavailable) says participant demographics are shown in Table 1, but the passages available from our copy do not give the racial breakdown. Searches for Caucasian, White, race, and ethnicity did not establish whether this trial was one of the four exceptions. This single trial also cannot establish the citing paper’s count across 34 studies. (LLM, conf=0.72)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,279 · see citing works
Untitled work
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115 · see citing works
Structured Clinical Interview for DSM-IV
(2007) · Sage eBooks · doi:10.4135/9781412952644.n443 · Cited by 725 · see citing works
The reliability of a timeline method for assessing normal drinker college students' recent drinking history: Utility for alcohol research
Sobell, M. B., Sobell, L. C., Klajner, F., Pavan, D., & Basian, E. (1986) · Addictive Behaviors · doi:10.1016/0306-4603(86)90040-7 · Cited by 468 · see citing works
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461 · see citing works
Multiple Imputation for Nonresponse in Surveys.
Kershaw, C. D., & Rubin, D. B. (1989) · Biometrics · doi:10.2307/2532070 · Cited by 392 · see citing works
Striatal Dopamine D <sub>2</sub> /D <sub>3</sub> Receptor Availability Is Reduced in Methamphetamine Dependence and Is Linked to Impulsivity
Lee, B., London, E. D., Poldrack, R. A., Farahi, J., Nacca, A., Monterosso, J. R., Mumford, J. A., Bokarius, A. V., Dahlbom, M., Mukherjee, J., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3765-09.2009 · Cited by 374 · see citing works
Text Message Intervention Designs to Promote Adherence to Antiretroviral Therapy (ART): A Meta-Analysis of Randomized Controlled Trials
Finitsis, D. J., Pellowski, J. A., & Johnson, B. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088166 · Cited by 355 · see citing works
Structure and Diagnosis of Adult Attention-Deficit/Hyperactivity Disorder: Analysis of Expanded Symptom Criteria From the Adult ADHD Clinical Diagnostic Scale
Kessler, R. C., Green, J. G., Adler, L. A., Barkley, R. A., Chatterji, S., Faraone, S. V., Finkelman, M., Greenhill, L. L., Gruber, M. J., Jewell, M., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.146 · Cited by 317 · see citing works
A systematic review of cognitive and behavioural therapies for methamphetamine dependence
Lee, N., & Rawson, R. A. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801919494 · Cited by 256 · see citing works
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234 · see citing works
A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse
Dwoskin, L. P., & Crooks, P. A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00899-1 · Cited by 219 · see citing works
Contingency Management for the Treatment of Methamphetamine Use Disorders
Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M., BLAINE, J. D., Macdonald, M. J., DiMaria, J., Lucero, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1993 · Cited by 196 · see citing works
Contingency Management for the Treatment of Methamphetamine Use Disorders
Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., Blaine, J., MacDonald, M., DiMaria, J., Lucero, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1993 · Cited by 196 · see citing works
Methamphetamine: History, Pathophysiology, Adverse Health Effects, Current Trends, and Hazards Associated with the Clandestine Manufacture of Methamphetamine
Vearrier, D., Greenberg, M. I., Miller, S. N., Okaneku, J., & Haggerty, D. A. (2012) · Disease-a-Month · doi:10.1016/j.disamonth.2011.09.004 · Cited by 191 · see citing works
Bupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving
Newton, T. F., Roache, J. D., Garza, R. D. L., FONG, T. W., Wallace, C. L., Li, S.-H., Elkashef, A. M., Chiang, N., & Kahn, R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300979 · Cited by 163 · see citing works
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
SHOPTAW, S. J., Heinzerling, K. G., Rotheram-Fuller, E. J., Steward, T., Wang, J., Swanson, A., Garza, R. D. L., Newton, T., & Ling, W. W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.010 · Cited by 150 · see citing works
Self-citation
Bupropion occupancy of the dopamine transporter is low during clinical treatment
Meyer, J. H., Goulding, V. S., Wilson, A. A., Hussey, D. F., Christensen, B. K., & Houle, S. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1166-3 · Cited by 147 · see citing works
Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis
Nomikos, G. G. (1989) · Neuropsychopharmacology · doi:10.1016/0893-133x(89)90031-6 · Cited by 131 · see citing works
Pharmacotherapy of amphetamine-type stimulant dependence: An update
Brensilver, M., Heinzerling, K., & Shoptaw, S. (2013) · Drug and Alcohol Review · doi:10.1111/dar.12048 · Cited by 122 · see citing works
Self-citation
Modafinil for the treatment of methamphetamine dependence
Anderson, A. L., Li, S.-H., Biswas, K., McSherry, F., Holmes, T. H., Iturriaga, E., Kahn, R., Chiang, N., Beresford, T. P., Campbell, J. L., et al. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.007 · Cited by 117 · see citing works
Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105 · see citing works
Self-citation
Dopamine transporter availability in medication free and in bupropion treated depression: A 99mTc-TRODAT-1 SPECT study
Árgyelán, M., Szabó, Z., Kanyó, B., Tanács, A., Kovács, Z. Z. A., Janka, Z., & Pávics, L. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.08.016 · Cited by 98 · see citing works
Towards empirical identification of a clinically meaningful indicator of treatment outcome: Features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes
Carroll, K., Kiluk, B. D., Nich, C., DeVito, E., Decker, S. E., LaPaglia, D. M., Duffey, D., Babuscio, T., & Ball, S. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.01.012 · Cited by 90 · see citing works
A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence.
Pettinati, H. M., Weiss, R. D., Dundon, W. D., Miller, W. R., Donovan, D. M., Ernst, D., & Rounsaville, B. J. (2005) · Journal of Studies on Alcohol Supplement · doi:10.15288/jsas.2005.s15.170 · Cited by 84 · see citing works
Bupropion increases striatal vesicular monoamine transport
Rau, K. S., Birdsall, E., Hanson, J. E., Johnson‐Davis, K. L., Carroll, F. I., Wilkins, D. G., Gibb, J. W., Hanson, G. R., & Fleckenstein, A. E. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.05.004 · Cited by 72 · see citing works
Safety of intravenous methamphetamine administration during treatment with bupropion
Newton, T. F., Roache, J. D., Garza, R. D. L., Fong, T., Wallace, C. L., Li, S.-H., Elkashef, A. M., Chiang, N., & Kahn, R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0102-8 · Cited by 63 · see citing works
A Multisite, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin for Treating Cocaine Dependence
Somoza, E. C., Winship, D., Gorodetzky, C. W., Lewis, D. F., Ciraulo, D. A., Galloway, G. P., Segal, S. D., Sheehan, M. B., Roache, J. D., Bickel, W. K., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.872 · Cited by 47 · see citing works
Psychometric evaluation of the Amphetamine Cessation Symptom Assessment
McGregor, C., Srisurapanont, M., Mitchell, A., Longo, M. C., Cahill, S., & White, J. M. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.05.007 · Cited by 47 · see citing works
Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration
Glick, S. D., Sell, E. M., & Maisonneuve, I. M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.09.038 · Cited by 46 · see citing works
Bupropion attenuates methamphetamine self-administration in adult male rats
Reichel, C. M., Murray, J. E., Grant, K. M., & Bevins, R. A. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.09.006 · Cited by 46 · see citing works
A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: Suggested guidelines for treatment discontinuation/augmentation
Brensilver, M., Heinzerling, K. G., Swanson, A., & SHOPTAW, S. J. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.03.027 · Cited by 43 · see citing works
Self-citation
Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables
Dean, A. C., London, E. D., Sugar, C. A., Ramirez, C. M., Swanson, A., Heinzerling, K. G., Kalechstein, A. D., & SHOPTAW, S. J. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.06.008 · Cited by 43 · see citing works
Self-citation
A Novel, Nonbinary Evaluation of Success and Failure Reveals Bupropion Efficacy Versus Methamphetamine Dependence: Reanalysis of a Multisite Trial
McCann, D. J., & Li, S. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00263.x · Cited by 41 · see citing works
Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area
Mansvelder, H. D., Fagen, Z. M., Chang, B., Mitchum, R. D., & McGehee, D. S. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.034 · Cited by 39 · see citing works
Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence
Simmler, L. D., Wandeler, R., & Liechti, M. E. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-220 · Cited by 38 · see citing works
Early Adoption of lnjectable Naltrexone for Alcohol-Use Disorders: Findings in the Private-Treatment Sector
Abraham, A. J., & Roman, P. M. (2010) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2010.71.460 · Cited by 36 · see citing works
An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation
Perkins, K. A., & Lerman, C. E. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3364-6 · Cited by 34 · see citing works
Assessment of riboflavin as a tracer substance: Comparison of a qualitative to a quantitative method of riboflavin measurement
Herron, A. J., Mariani, J. J., Pavlicová, M., Parrinello, C. M., Bold, K. W., LEVIN, F. R., Nunes, E. V., Sullivan, M. A., Raby, W. N., & Bisaga, A. M. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.08.007 · Cited by 34 · see citing works
Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys.
Schindler, C. W., Gilman, J. P., Panlilio, L. V., McCann, D. J., & Goldberg, S. R. (2011) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0022432 · Cited by 32 · see citing works
Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study
Egerton, A., Shotbolt, J. P., Stokes, P. R. A., Hirani, E., Ahmad, R., Lappin, J., Reeves, S., Mehta, M. A., Howes, O. D., & Grasby, P. M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.11.077 · Cited by 31 · see citing works
A Simple, Novel Method for Assessing Medication Adherence
Galloway, G. P., Coyle, J., Guillén, J. E., Flower, K., & Mendelson, J. E. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181fcb5fd · Cited by 25 · see citing works
Factor structure of the Barratt impulsiveness scale
Patton, J. H., Stanford, M. S., & Barratt, E. S. (1995) · Journal of Clinical Psychology · doi:10.1002/1097-4679(199511)51:6

Flagged first, then by citations

Sorted by citations

Bupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281 · see citing works
Self-citation
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194 · see citing works
Pharmacotherapeutic agents in the treatment of methamphetamine dependence
Morley, K. C., Cornish, J. L., Faingold, A., Wood, K., & Haber, P. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313229 · Cited by 108 · see citing works
Impact of an exercise intervention on methamphetamine use outcomes post-residential treatment care
Rawson, R. A., Chudzynski, J. E., Mooney, L. J., Gonzales, R. E., Ang, A., Dickerson, D. L., Peñate, J., Salem, B. A., Dolezal, B. A., & Cooper, C. B. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.029 · Cited by 92 · see citing works
Pharmacotherapy for amphetamine dependence: A systematic review
Lee, N., Jenner, L., Harney, A., & Cameron, J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.06.038 · Cited by 85 · see citing works
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78 · see citing works
Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial
Anderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70 · see citing works
Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis
Bhatt, M., Zielinski, L., Baker-Beal, L., Bhatnagar, N., Mouravska, N., Laplante, P., Worster, A., Thabane, L., & Samaan, Z. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0370-x · Cited by 56 · see citing works
Interactions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects
Schmid, Y., Rickli, A., Schaffner, A., Duthaler, U., Grouzmann, E., Hysek, C. M., & Liechti, M. E. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222356 · Cited by 51 · see citing works
Extended‐release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo‐controlled trial
Coffin, P. O., Santos, G., Hern, J., Vittinghoff, E., Santos, D., Matheson, T., Colfax, G. N., & Batki, S. L. (2017) · Addiction · doi:10.1111/add.13950 · Cited by 45 · see citing works
Psychostimulants
McCreary, A. C., Müller, C. P., & Filip, M. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.02.008 · Cited by 44 · see citing works
Molecular Mechanisms of Amphetamines.
Reith, M., & Gnegy, M. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_251 · Cited by 32 · see citing works
Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings
Härtel-Petri, R., Krampe-Scheidler, A., Braunwarth, W.-D., Havemann-Reinecke, U., Jeschke, P., Looser, W., Mühlig, S., Schäfer, I., Scherbaum, N., Bothe, L., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-105500 · Cited by 39 · see citing works
Methamphetamine Toxicities and Clinical Management
Coffin, P. O., & Suen, L. W. (2023) · NEJM Evidence · doi:10.1056/evidra2300160 · Cited by 36 · see citing works
The impact of amphetamine-type stimulants on emergency services
Fulde, G., & Forster, S. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000171 · Cited by 34 · see citing works
Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine
Stoops, W. W., Pike, E., Hays, L. R., Glaser, P. E. A., & Rush, C. R. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.11.018 · Cited by 32 · see citing works
Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups
Soares, E. F. P., & Pereira, F. C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1681970 · Cited by 31 · see citing works
Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder
Heinzerling, K. G., Briones, M., Thames, A. D., Hinkin, C. H., Zhu, T., Wu, Y. N., & Shoptaw, S. J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09883-w · Cited by 30 · see citing works
Self-citation
Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence
Cook, R., Quinn, B., Heinzerling, K. G., & SHOPTAW, S. J. (2017) · Addiction · doi:10.1111/add.13765 · Cited by 28 · see citing works
Self-citation
Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder
Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., Chang, L., Walker, R., Trivedi, M., Croteau, D., et al. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000218 · Cited by 25 · see citing works
Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials
Bakouni, H., Sharafi, H., Bahremand, A., Drouin, S., Ziegler, D., Bach, P., Foll, B. L., Schütz, C. G., Tardelli, V. S., Ezard, N., et al. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.111018 · Cited by 23 · see citing works
Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys
Banks, M., & Blough, B. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.63 · Cited by 25 · see citing works
Methamphetamine Use
Fogger, S. A. (2019) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000298 · Cited by 22 · see citing works
Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?
Mikelman, S. R., Mardirossian, N., & Gnegy, M. E. (2016) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2016.08.004 · Cited by 20 · see citing works
Multiple comparison of different noninvasive brain stimulation and pharmacologic interventions in patients with methamphetamine use disorders: A network meta‐analysis of randomized controlled trials
Wu, M.-K., Satogami, K., Liang, C.-S., Stubbs, B., Carvalho, A. F., Brunoni, A., Su, K., Tu, Y.-X., Wu, Y.-C., Chen, T.-Y., et al. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13452 · Cited by 15 · see citing works
Self-citation
Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial
Briones, M. S., SHOPTAW, S. J., Cook, R., Worley, M. J., Swanson, A., Moody, D. E., Fang, W. B., TSUANG, J. W., Furst, B. A., & Heinzerling, K. G. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.04.023 · Cited by 17 · see citing works
Self-citation
The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats
Pittenger, S. T., Barrett, S. T., Chou, S., & Bevins, R. A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.11.033 · Cited by 16 · see citing works
Immunopharmacotherapeutic advancements in addressing methamphetamine abuse
Lee, J. C., & Janda, K. D. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00165a · Cited by 16 · see citing works
Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder
Banks, M. L. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13276 · Cited by 18 · see citing works
Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial
Li, M. J., Chau, B., Belin, T. R., Carmody, T. J., Jha, M. K., Marino, E. N., Trivedi, M. H., & SHOPTAW, S. J. (2024) · Addiction · doi:10.1111/add.16529 · Cited by 14 · see citing works
Self-citation
Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature
Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292745 · Cited by 13 · see citing works
Craving among individuals with stimulant use disorder in residential social model-based treatment – Can exercise help?
Salem, B. A., Gonzales-Castaneda, R., Ang, A., Rawson, R. A., Dickerson, D. L., Chudzynski, J. E., Peñate, J., Dolezal, B. A., Cooper, C. B., & Mooney, L. J. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109247 · Cited by 14 · see citing works
A mechanistic overview of approaches for the treatment of psychostimulant dependence
Jensen, K. L., Jensen, S. B., & Madsen, K. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854176 · Cited by 12 · see citing works
Effects of the GluN2B-selective antagonist Ro 63-1908 on acquisition and expression of methamphetamine conditioned place preference in male and female rats
Yates, J. R., Campbell, H. L., Hawley, L. L., Horchar, M. J., Kappesser, J. L., & Wright, M. R. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108785 · Cited by 12 · see citing works
Identification of Treatment Targets in a Genetic Mouse Model of Voluntary Methamphetamine Drinking
Phillips, T. J., Mootz, J. R. K., & Reed, C. L. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.001 · Cited by 12 · see citing works
Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses
Lim, A. C., Grodin, E. N., Green, R., Venegas, A., Meredith, L. R., Courtney, K. E., Moallem, N. R., Sayegh, P., London, E. D., & Ray, L. A. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1741002 · Cited by 11 · see citing works
Commentary on H einzerling et al. (2014): A growing methamphetamine dependence therapeutics graveyard
Carson, D. S., & Taylor, E. R. (2014) · Addiction · doi:10.1111/add.12709 · Cited by 11 · see citing works
Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission.
Hankosky, E. R., Bush, H., Dwoskin, L. P., Harris, D. R., Henderson, D. W., Zhang, G., Freeman, P. R., & Talbert, J. (2018) · Europe PMC (PubMed Central) · Cited by 10 · see citing works
Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial
Schmitz, J. M., Stotts, A. L., Yoon, J. H., Northrup, T. F., Villarreal, Y. R., Yammine, L., Weaver, M. F., Carmody, T. J., SHOPTAW, S. J., & Trivedi, M. H. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.208987 · Cited by 9 · see citing works
Self-citation
Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders
Amin‐Esmaeili, M., Susukida, R., Johnson, R. M., Farokhnia, M., Crum, R. M., Thrul, J., & Mojtabai, R. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108904 · Cited by 8 · see citing works
Understanding Regional Patterns of Overdose Deaths Related to Opioids and Psychostimulants
Segel, J. E., Shearer, R. D., Jones, A. A., Khatri, U. G., Howell, B. A., Crowley, D. M., Sterner, G., Vest, N. A., da Silva, D. T., & Winkelman, T. N. A. (2023) · Substance Use & Misuse · doi:10.1080/10826084.2023.2287220 · Cited by 8 · see citing works
Efficacy of bupropion and cognitive behavioral therapy in the treatment of methamphetamine use disorder: a systematic review and meta-analysis
Apuy, L. F. M., Barreto, M., & Merino, L. A. H. (2023) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2022-2979 · Cited by 8 · see citing works
Effects of methamphetamine-induced neurotoxicity on striatal long-term potentiation
Gibson, A. S., West, P. J., & Keefe, K. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06055-8 · Cited by 7 · see citing works
Single nucleotide polymorphism near CREB1, rs7591784, is associated with pretreatment methamphetamine use frequency and outcome of outpatient treatment for methamphetamine use disorder
Heinzerling, K. G., Demirdjian, L., Wu, Y., & SHOPTAW, S. J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.12.008 · Cited by 7 · see citing works
Self-citation
Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial
LEVIN, F. R., Mariani, J. J., Pavlicová, M., Choi, C. J., Basaraba, C. N., Mahony, A. L., Brooks, D. J., Brezing, C., & Naqvi, N. H. (2024) · Journal of Attention Disorders · doi:10.1177/10870547241264675 · Cited by 7 · see citing works
Therapeutic targeting of neuroinflammation in methamphetamine use disorder
Jeffery, N., Mock, P. Y., Yang, K., Tham, C. L., Israf, D. A., Li, H., Wang, X., & Lam, K. W. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2447226 · Cited by 7 · see citing works
Case Report: Unusual oral cavity changes associated with methamphetamine abuse
Скрипник, М. І., Skrypnyk, R. І., Петрушанко, Т. О., Skikevych, M., Petrushanko, V., & Скрипник, І. М. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1473584 · Cited by 6 · see citing works
Role of vesicular monoamine transporter-2 for treating attention deficit hyperactivity disorder: a review
Warlick, H., Tocci, D. R., Prashar, S., Boldt, E. A., Khalil, A., Arora, S., Matthews, T., Wahid, T., Fernandez, R., Ram, D., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06686-7 · Cited by 4 · see citing works
Disorders due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_26 · Cited by 3 · see citing works
Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten
Kiefer, F., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_7 · Cited by 2 · see citing works
Psychological Effects of 12 Weeks of Moderate-to-Vigorous Exercise on Men With Methamphetamine Use Disorder: A Randomized Controlled Trial
Tang, Z., Zhu, Z., Ma, X., Lin, Y., Xu, J., Zhou, Q., Hu, B., Li, X., & He, Y. (2025) · Substance Use &amp Addiction Journal · doi:10.1177/29767342251352608 · Cited by 2 · see citing works
Types of addiction
Turpin, M. A. C., Rowland, K. C., Anugwom, C., Arocha, M., Carona, A., Gonzalez, B. I., Iskander, G., Snyder, S., Wilson, K., Kaye, A. D., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98814-8.00027-5 · Cited by 2 · see citing works
Methamphetamine Use Among Sexual Minority Men
Lodge, W., Biello, K. B., Valente, P. K., & Mimiaga, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_109 · Cited by 2 · see citing works
Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten
Kiefer, F., & Benkert, O. (2016) · Springer eBooks · doi:10.1007/978-3-662-50333-1_7 · Cited by 1 · see citing works
Perinatal Methamphetamine Use: A Review of the Literature
Hickert, A., Rowley, B., & Doyle, M. (2021) · Psychiatric Annals · doi:10.3928/00485713-20210303-01 · Cited by 1 · see citing works
Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten
Kiefer, F., & Benkert, O. (2020) · Springer eBooks · doi:10.1007/978-3-662-61753-3_7 · Cited by 1 · see citing works
What Can We Expect from the Pharmacological Treatments for Dependences Presently Available?
Justo, L. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-43172-7_3
Pharmacotherapy of Addiction to Amphetamine-Type Stimulants
Elkashef, A. M., & Khalsa, J. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_14
Methamphetamine Use Among Sexual Minority Men
Lodge, W., Biello, K. B., Valente, P. K., & Mimiaga, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_109-1
Medikamente zur Behandlung von Abhängigkeit und Entzugssyndromen
Benkert, O. (2014) · Springer eBooks · doi:10.1007/978-3-642-54769-0_7
Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten
Kiefer, F., & Benkert, O. (2018) · Springer eBooks · doi:10.1007/978-3-662-57334-1_7
Disorders Due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_26-1
Baseline Moderators of Response to Naltrexone and Bupropion in the Treatment of Methamphetamine Use Disorder: An ADAPT-2 Study
Carmody, T. J., Mayes, T. L., Jha, M. K., SHOPTAW, S. J., & Trivedi, M. H. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001533
Self-citation
Chapter 6. Stimulants
Kampman, K. M. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg06

Bupropion for methamphetamine dependence
Heinzerling, K. G., Swanson, A., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014) · eScholarship (California Digital Library)
Self-citation
Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial
Anderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70 · see citing works
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234 · see citing works
Randomized trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use
Heinzerling, K. G., Hall, T., Swanson, A., & SHOPTAW, S. J. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.02.249 · Cited by 2 · see citing works
Self-citation
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
SHOPTAW, S. J., Heinzerling, K. G., Rotheram-Fuller, E. J., Steward, T., Wang, J., Swanson, A., Garza, R. D. L., Newton, T., & Ling, W. W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.010 · Cited by 150 · see citing works
Self-citation

Authors: Heinzerling, K. G., Swanson, A., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J.
Affiliations: University of California, Los Angeles (US)
Corresponding author: Heinzerling, Keith G.
ORCID: Heinzerling, Keith G.
Hall, Timothy M.
Yi, Yi
Wu, Yingnian
Shoptaw, Steven J.
Venue: Addiction
Publisher: Wiley
Published: 2014-08-05
Volume: 109
Issue: 11
Pages: 1878-1886
ISSN: 0965-2140 (ISSN-L)
1360-0443
DOI: 10.1111/add.12636
PMC: PMC4192025
OpenAlex: W1483496794
Cited by: 64
References: 42
Citations by year: 2025: 4 · 2024: 6 · 2023: 9 · 2022: 5 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 7 · 2015: 8 · 2014: 3
FWCI: 5.56
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Addiction (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institute on Drug Abuse (DA023558, DA026400)
Topics: Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: bupropion, methamphetamine dependence, medication adherence, outpatient counseling
MeSH terms: Assessment of Medication Adherence, Adult, Female, Humans, Male, Methamphetamine, Middle Aged, Bupropion, Treatment Outcome, Drug Monitoring, Dopamine Uptake Inhibitors, Amphetamine-Related Disorders, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks